IDEXX Laboratories: The Future of Veterinary Diagnostics Looks Bright.

IDEXX Laboratories is a leading company in veterinary diagnostics, helping veterinarians diagnose and monitor the health of pets through in-clinic testing machines, laboratory services, and software solutions. From its widely used diagnostic platforms such as Catalyst and inVue Dx to newer innovations like Cancer Dx and cloud-based clinic software, the company combines recurring revenue with strong customer loyalty and continuous innovation. With long-term tailwinds from pets increasingly being treated as family members, an aging pet population, and growing demand for preventive care, IDEXX Laboratories is well positioned for continued growth in animal healthcare. The question remains: Does this veterinary healthcare leader deserve a spot in your portfolio?

This is not a financial advice. I am not a financial advisor and I only do these post in order to do my own analysis and elaborate about my decisions, especially for my copiers and followers. If you consider investing in any of the ideas I present, you should do your own research or contact a professional financial advisor, as all investing comes with a risk of losing money. You are also more than welcome to copy me. 

For full disclosure, I should mention that I do not own any shares in IDEXX Laboratories at the time of writing this analysis. If you would like to copy or view my portfolio, you can find instructions on how to do so here. If you want to purchase shares or fractional shares of IDEXX Laboratories, you can do so through eToro. eToro is a highly user-friendly platform that allows you to get started on investing with as little as $50.

The Business

IDEXX Laboratories was founded in 1983 and has grown into the global leader in veterinary diagnostics, software, and water testing solutions. The company operates a highly integrated business model centered around diagnostic instruments, consumables, laboratory services, software, and information management systems, with the vast majority of its revenue and profits generated by its Companion Animal Group. This segment serves veterinary clinics and hospitals worldwide by providing a full suite of in-clinic diagnostic analyzers, rapid assay tests, reference laboratory services, diagnostic imaging systems, and cloud-based practice management software. The business model is built around becoming deeply embedded in the daily workflow of veterinary practices. Veterinarians use IDEXX’s instruments to run blood chemistry, hematology, urinalysis, immunoassay, and imaging tests directly in the clinic, while more advanced or specialized samples can be sent to IDEXX’s global network of approximately 80 reference laboratories. All of this diagnostic data is integrated through its cloud-based software ecosystem, including VetConnect PLUS, practice management systems such as ezyVet, Cornerstone, and Neo, and imaging platforms such as Web PACS. This allows veterinarians to access patient history, test results, diagnostic trends, and imaging data through one connected platform, improving workflow efficiency and clinical decision-making. A defining feature of IDEXX’s business model is its razor-and-blade structure. The company places its diagnostic instruments in clinics and then generates highly recurring, high-margin revenue from the ongoing sale of consumables such as reagents, cartridges, slides, rapid test kits, service agreements, software subscriptions, and laboratory services. This creates a highly predictable revenue stream and gives the business financial characteristics similar to a high-quality SaaS company, despite its physical hardware component. While the Companion Animal Group is by far the most important segment, IDEXX also operates in water quality testing and livestock, poultry, and dairy diagnostics. The Water segment provides testing products used by utilities, government agencies, and laboratories to detect microbiological contamination in drinking water, wastewater, and industrial water systems. The Livestock, Poultry, and Dairy segment offers diagnostic solutions for animal health monitoring and milk safety. These segments are smaller but provide additional diversification and stable cash flow. IDEXX’s competitive moat is primarily built on its integrated ecosystem, high switching costs, recurring revenue model, and strong brand reputation within veterinary healthcare. The company has created what is effectively the operating system for veterinary practices. Its instruments, software, laboratory services, and cloud-based platforms are deeply embedded in the day-to-day operations of clinics. Once a clinic adopts IDEXX’s analyzers and software, switching becomes highly disruptive because the entire workflow, including staff training, patient data history, lab integration, billing, and client communication, is built around the IDEXX ecosystem. This creates significant switching costs and contributes to customer retention rates in the high 90s. Another major competitive advantage is the scale and breadth of its diagnostic offering. IDEXX provides a comprehensive end-to-end solution that few competitors can replicate. A clinic can run in-house diagnostics, send complex tests to IDEXX’s reference labs, store and analyze data through its software, and access AI-enhanced diagnostic support all within one platform. Replicating this ecosystem would require substantial investment in research and development, laboratory infrastructure, software engineering, distribution, and customer support, creating a meaningful barrier to entry. The company’s installed base of instruments further strengthens the moat through recurring consumables revenue. Once instruments are placed, every test run on those machines generates additional sales of reagents and cartridges, creating a recurring revenue stream that compounds over time as clinics grow their testing volumes. This razor-and-blade model supports strong margins and highly predictable cash flow. IDEXX’s brand strength and long-standing relationships with veterinarians also reinforce its moat. In veterinary diagnostics, reliability and consistency are critical because diagnostic accuracy directly impacts patient outcomes. Over decades, IDEXX has built a reputation for high-quality diagnostics and strong customer support, making veterinarians less likely to experiment with alternative providers. Continuous innovation also strengthens the moat. The company continues to launch new diagnostic tools, imaging solutions, and advanced testing capabilities such as cancer diagnostics, which further deepen customer reliance on its platform. Combined with its scale, data advantages, global laboratory network, and software integration, IDEXX has built a durable competitive position that is extremely difficult for competitors to challenge.

Management

Michael Erickson will serve as the President and CEO of IDEXX Laboratories from May 12, 2026, succeeding Jonathan Mazelsky after a carefully planned internal succession process. His appointment reflects continuity rather than strategic disruption, as he has spent more than 15 years in increasingly senior leadership roles within IDEXX and has developed deep operational knowledge across many of the company’s most important business areas. This internal promotion is particularly noteworthy because IDEXX’s moat is built on an integrated ecosystem of diagnostics, software, data, and customer relationships, making institutional knowledge and continuity especially valuable. Michael Erickson brings a strong combination of scientific, technological, and commercial expertise that appears highly aligned with IDEXX’s long-term strategy of innovation-led growth and deep customer integration. Before becoming CEO, Michael Erickson most recently served as Executive Vice President and General Manager of IDEXX’s Global Point of Care Diagnostics and Telemedicine business. This is one of the company’s most strategically important divisions, as it sits at the heart of IDEXX’s in-clinic diagnostic ecosystem and recurring consumables model. In this role, he was responsible for the development and commercial execution of products that are deeply embedded in veterinary clinic workflows, including diagnostic analyzers, telemedicine capabilities, and AI-enabled diagnostic tools. This experience is highly relevant because point-of-care diagnostics is one of the most important drivers of IDEXX’s recurring revenue growth and customer retention. Prior to this role, Michael Erickson held several senior leadership positions across IDEXX’s software, diagnostics, strategy, and corporate accounts businesses. He previously led Veterinary Software and Services, where he gained direct exposure to IDEXX’s practice management systems and cloud-based workflow tools such as ezyVet, Cornerstone, and VetConnect PLUS. He also led Corporate and Strategic Accounts and oversaw parts of the company’s strategy and advanced analytics functions. This breadth of experience is particularly important because it means he understands not only the product side of the business but also the commercial relationships, customer retention drivers, and data infrastructure that underpin IDEXX’s competitive moat. Before joining IDEXX in 2011, Michael Erickson worked as an Associate Principal in McKinsey’s Global Pharmaceutical Practice, where he gained experience in healthcare strategy and operational improvement. He holds a PhD in Biomedical Engineering from Johns Hopkins University School of Medicine and a Bachelor of Science in Electrical Engineering from Purdue University. This combination of scientific depth and strategic business experience gives him a profile that is well suited to lead a company whose competitive strength depends on diagnostic accuracy, software integration, and continuous product innovation. Management’s own comments on the transition are also highly reassuring. Jonathan Mazelsky explicitly stated that Michael Erickson is uniquely suited for the role, highlighting his leadership across diagnostics, software, commercial teams, and corporate accounts, as well as his innovative capabilities. The fact that Jonathan Mazelsky will remain as Executive Chair until 2027 further supports a smooth transition and reduces execution risk during the handover period. For a business like IDEXX, where customer trust, innovation cadence, and ecosystem continuity are essential, this kind of structured leadership transition is an important positive. From an investor perspective, Michael Erickson appears exceptionally well suited to lead IDEXX through its next phase of growth. His deep understanding of the company’s diagnostics ecosystem, software infrastructure, and recurring revenue model aligns closely with the drivers that have historically made IDEXX such a high-quality compounder. Rather than representing a strategic reset, his appointment suggests continued focus on innovation, customer retention, and expansion of IDEXX’s integrated veterinary platform, which is likely exactly what long-term shareholders want to see.

The Numbers

The first number we will look into is the return on invested capital, also known as ROIC. We want to see a 10-year history, with all numbers exceeding 10% in each year. IDEXX has historically generated exceptionally high ROIC, and the numbers here are remarkable. From 2016 to 2025, ROIC has remained consistently between 38,0% and 63,7%, with every single year far above the 10% threshold we typically look for. Even the lowest year in this period, 2024 at 38.0%, would still be considered exceptional for almost any company. This level of consistency strongly suggests that IDEXX’s high returns are not driven by temporary factors but by structural advantages embedded in the business model. Several characteristics explain why the company has been able to maintain such elevated returns on capital over a long period. First, IDEXX benefits from a razor-and-blade business model that is exceptionally capital efficient. The company places diagnostic instruments in veterinary clinics and then generates recurring, high-margin revenue from consumables such as reagents, cartridges, rapid test kits, service agreements, and software subscriptions. Once the instruments are installed, each additional test creates revenue with very limited incremental capital required. This is one of the main reasons why the company can consistently produce ROIC in the 40% range. The installed base effectively becomes a recurring revenue engine that compounds over time. Second, the company’s integrated ecosystem creates extremely high switching costs and supports very high customer retention. Veterinary clinics do not simply buy a machine from IDEXX. They adopt a connected workflow that includes diagnostic instruments, cloud-based software, laboratory services, imaging, patient records, and communication tools. Once this system is embedded into daily practice operations, switching becomes costly and disruptive. This is reflected in customer retention rates in the high 90s. Because IDEXX retains customers so effectively, it can continue growing revenue from its existing installed base without needing large reinvestments in capital, which significantly supports ROIC. Third, the company benefits from strong operating leverage. The laboratory network, software infrastructure, and installed analyzer base all scale very well as testing volumes increase. Higher pet healthcare spending and increased diagnostic penetration allow IDEXX to generate more revenue from existing assets. This is particularly visible in years such as 2018, when ROIC reached 63,7%, likely reflecting exceptionally strong earnings growth relative to the capital base. Even though ROIC normalized after that unusually high level, it has remained consistently close to or above 40%, which is still extraordinary. The dip from 63,7% in 2018 to the high 30s and low 40s in later years should not be interpreted as a deterioration in the business. In fact, it more likely reflects a normalization as IDEXX continued investing in innovation, software, laboratory capacity, and new products, which naturally increased the invested capital base. At the same time, the company still maintained ROIC levels between 38% and 46% in most years, which shows that incremental investments continue to generate very attractive returns. Looking ahead, I believe ROIC is likely to remain exceptionally high, although it may not consistently return to the 60% level seen in 2018. The key drivers remain fully intact: recurring consumables revenue, extremely high retention, strong pricing power, and long-term secular growth driven by the humanization of pets. Continued investment in diagnostics, software, and new test categories such as oncology may increase the capital base somewhat, which could keep ROIC closer to the 35% to 45% range rather than above 50%. However, that would still place IDEXX among the very best businesses globally in terms of capital efficiency. In my view, the structure of the business strongly supports continued ROIC at exceptionally high levels for many years.

The next numbers are the book value + dividend. In my old format this was known as the equity growth rate. It was the most important of the four growth rates I used to use in my analyses, which is why I will continue to use it moving forward. As you are used to see the numbers in percentage, I have decided to share both the numbers and the percentage growth year over year. To put it simply, equity is the part of the company that belongs to its shareholders – like the portion of a house you truly own after paying off part of the mortgage. Growing equity over time means the company is becoming more valuable for its owners. So, when we track book value plus dividends, we’re essentially looking at how much value is being built for shareholders year after year. The next numbers are the book value plus dividend. In my old format this was known as the equity growth rate. It was the most important of the four growth rates I used to use in my analyses, which is why I will continue to use it moving forward. As you are used to seeing the numbers in percentage, I have decided to share both the numbers and the percentage growth year over year. To put it simply, equity is the part of the company that belongs to its shareholders, like the portion of a house you truly own after paying off part of the mortgage. Growing equity over time means the company is becoming more valuable for its owners. So, when we track book value plus dividends, we are essentially looking at how much value is being built for shareholders year after year. IDEXX’s equity development over the past decade looks unusually volatile at first glance, and the negative equity in the early years may seem concerning. However, in this case it is much more a reflection of capital allocation than of business weakness. The negative equity seen from 2016 through 2018 was primarily driven by the company’s aggressive share repurchase programs. IDEXX has historically generated very strong free cash flow and exceptionally high returns on capital, and management has chosen to return a significant portion of that excess cash to shareholders through buybacks. When a company buys back its own shares, the cash used for those purchases reduces the equity on the balance sheet. If buybacks are large enough, equity can even become negative despite the company being highly profitable. This is exactly what we see in IDEXX’s case. The business itself was performing very well during these years, as reflected by the extremely high ROIC figures, but the balance sheet equity was pushed below zero by capital returns to shareholders. The sharp move from negative equity in 2018 to a strong positive figure in 2019 is largely explained by continued profit growth eventually outweighing the impact from buybacks. Once cumulative profits began to exceed the reduction caused by share repurchases, equity turned positive again. This is why the percentage growth in 2019 appears extremely high at 1.870.0%. Such a number is mathematically distorted because the starting point was close to zero and negative in the prior year. The same applies to the very large percentage increase in 2020. These percentage figures should therefore be interpreted with caution, as the absolute movement in equity is more informative than the growth rate when the base is near zero. From 2020 onward, equity has generally remained positive and has continued to grow, although growth has clearly been volatile. This volatility is largely driven by three factors. First, strong net income increases equity. Second, share repurchases continue to reduce equity. Third, accounting adjustments such as currency movements and stock-based compensation can create year-to-year swings. The decline in 2022, for example, does not necessarily suggest weaker value creation but may simply reflect a year in which capital returned to shareholders exceeded the increase from profits. Importantly, volatility in equity growth is not unusual for a business like IDEXX. Because the company generates such high returns on capital, it does not need to retain large amounts of capital to fund growth. This is actually a sign of strength rather than weakness. Looking ahead, I would expect equity growth to remain somewhat volatile rather than showing a smooth upward trend every single year. As long as IDEXX continues to generate strong free cash flow and maintain high ROIC, management is likely to continue using share buybacks as an important part of capital allocation. This means there may be years where equity growth is modest or even negative despite strong operating performance. Over the long term, however, profits should continue to gradually increase equity as the business expands.

Finally, we will analyze the free cash flow. Free cash flow, in short, refers to the cash that a company generates after covering its operating expenses and capital expenditures. I use levered free cash flow margin because I believe that margins offer a better understanding of the numbers. Free cash flow yield refers to the amount of free cash flow per share that a company is expected to generate in relation to its market value per share. IDEXX has historically generated strong free cash flow and very attractive free cash flow margins, and the development over the past decade clearly highlights the strength of the business model. Free cash flow has increased from 274 in 2016 to a record 1.057 in 2025, while the free cash flow margin has expanded from 15,4% to 24,6%. Reaching a record level in 2025 is particularly impressive and reflects both strong profitability and excellent cash conversion. Several structural characteristics explain why IDEXX has consistently been such a strong cash-generating business. One of the main drivers is the company’s highly recurring revenue model. A large part of IDEXX’s revenue comes from consumables, diagnostic cartridges, reagents, reference laboratory services, software subscriptions, and maintenance agreements. These revenue streams are recurring in nature and require relatively limited additional capital once the installed base is in place. Every time a veterinary clinic runs another test on an IDEXX analyzer, it generates additional revenue and cash flow without requiring meaningful new investments. This razor-and-blade model is one of the most important reasons why free cash flow margins have remained so high. Another reason is that IDEXX operates with strong margins and relatively modest capital expenditure needs. In 2025, capital spending was only $125 million, which was approximately 3% of revenue. This is very low for a company with such a large installed base and global laboratory network. Even in 2026, management expects capital spending to rise to around 4% of revenue, which still remains modest relative to the earnings power of the business. Because the company does not need to reinvest a large portion of its revenue just to maintain growth, a substantial share of earnings turns into free cash flow. The continued expansion in free cash flow margin from 20.7% in 2024 to a record 24.6% in 2025 mainly reflects that IDEXX was able to grow revenue much faster than its costs. As more veterinary clinics use IDEXX’s analyzers and reference laboratory services, a large part of each additional dollar of revenue turns into cash because the systems and infrastructure are already in place. In simple terms, once the machines are installed and the laboratories are running, higher test volumes do not require equally large increases in costs. The software business also helps because it can grow without requiring significant additional spending. In 2025, management noted that free cash flow reached 100% of net income, which is exceptionally strong and shows just how effectively the company turns its profits into real cash. Looking ahead, I believe IDEXX should continue to remain a strong generator of free cash flow, although 2025 may represent an unusually strong year in terms of margin. Management expects free cash flow conversion in 2026 to be between 85% and 95% of net income, which is slightly below 2025 but still extremely attractive and aligned with the company’s long-term potential. The expected increase in capital spending to 4% of revenue may cause some short-term moderation in free cash flow margin, but this does not suggest any deterioration in the underlying business. Rather, it reflects continued investment in growth, innovation, and laboratory capacity. Over the long term, the combination of recurring revenue, high retention, strong pricing power, and limited capital needs suggests that IDEXX should continue generating free cash flow margins well above the average healthcare company. IDEXX primarily uses its free cash flow in two ways. First, part of the cash is reinvested into the business through product innovation, software development, AI-enabled diagnostics, laboratory capacity, and commercial expansion. These investments help strengthen the company’s moat and support future growth. Second, and perhaps most importantly from a shareholder perspective, a large portion of the free cash flow is returned to shareholders through share repurchases. In 2025, IDEXX allocated $1,2 billion to repurchase 2,4 million shares, reducing diluted shares outstanding by 2,7% year over year. Management has indicated that buybacks will remain an important use of cash in 2026, with a targeted 1% to 2% reduction in diluted shares outstanding. This disciplined capital allocation is one of the reasons why IDEXX has been able to compound shareholder value so effectively over time. The free cash flow yield is at its highest level in the past decade. While this does not necessarily mean that the shares are cheap, it does suggest that the valuation is the most attractive it has been in more than a decade. However, we will revisit valuation later in the analysis.

Debt

Another important aspect to consider is the level of debt. It is crucial to determine whether a business has manageable debt that can be repaid within a three-year period, which we calculate by dividing total long-term debt by earnings. After analyzing IDEXX’s financials, I found that the company has only 0,06 years of earnings in long-term debt, making this a non-issue from an investment perspective. In fact, IDEXX has actively prioritized debt reduction, and its long-term debt is now at its lowest level in the past decade. Given this strategic focus and the company’s strong cash generation, I do not expect debt to become a concern in the future either.

Support the Blog

I want to keep the blog free and accessible for everyone. If you enjoy the content and would like to support it, you can buy me a cup of coffee through PayPal. Every little bit helps and is truly appreciated!

Risks

Competition is a risk for IDEXX Laboratories because the companion animal healthcare industry is highly attractive, fast growing, and supported by strong returns on capital, which naturally attracts both large incumbents and new entrants. While IDEXX currently holds a leading position in veterinary diagnostics and software, maintaining this leadership requires continuous innovation, strong execution, and the ability to justify premium pricing. The company competes against several well-funded players, most notably Zoetis, Mars Incorporated through its Antech Diagnostics and Heska operations, as well as smaller specialized companies focused on imaging, software, or specific diagnostic niches. These competitors have substantial financial resources and strategic incentives to invest aggressively in research and development, expand product offerings, and compete on price. One of the most important competitive risks is pricing pressure. IDEXX has historically been able to charge premium prices because its products are widely regarded as the gold standard in veterinary diagnostics, supported by strong accuracy, workflow integration, and customer support. However, many competitors offer lower-cost alternatives. If the technology gap narrows over time, veterinary clinics may become more willing to switch or diversify suppliers, particularly in periods where clinics themselves face margin pressure. Because IDEXX’s business model relies on placing instruments that then drive recurring consumable sales, any slowdown in instrument placements or pressure on consumable pricing could have a meaningful impact on long-term revenue growth and margins. Another significant risk comes from corporate consolidation in veterinary care. Mars Incorporated is particularly important here because it owns some of the largest veterinary hospital networks in the world, including Banfield, VCA, and BluePearl, while also owning Antech and Heska within diagnostics. This creates a strong strategic incentive for Mars to direct more diagnostic volumes toward its own platforms rather than IDEXX. Even if IDEXX’s products remain superior, there is a risk that internal corporate decisions could prioritize in-house solutions, which may place a ceiling on IDEXX’s penetration within large corporate veterinary groups. Zoetis also represents a meaningful competitive threat because it combines diagnostics with leadership in animal pharmaceuticals. This creates the possibility of bundling, where clinics may receive attractive pricing if they commit to both diagnostic systems and pharmaceutical products. Since many veterinary practices rely heavily on Zoetis drugs such as Apoquel and Cytopoint, this bundling strategy could pressure IDEXX’s pricing and customer retention over time. In addition, Zoetis continues to invest in diagnostic innovation through products such as VetScan and AI-enabled platforms, which may gradually narrow the competitive gap. Competition is also a risk because IDEXX must continuously innovate to maintain its moat. Its strong market position depends on keeping its diagnostic instruments, software, AI tools, and reference laboratory services ahead of peers. If competitors launch more advanced or equally effective solutions, particularly at lower prices, IDEXX may face slower growth in its installed base and lower recurring revenue growth. This is especially important because the company’s premium valuation partly reflects the expectation that it will continue to grow at attractive rates for many years.

Macroeconomic factors are a risk for IDEXX Laboratories because demand for a meaningful part of its business is ultimately linked to consumer spending, veterinary visit volumes, and the financial health of clinics and institutions. While pet healthcare tends to be more resilient than many other consumer categories, it is not fully immune to economic pressure. IDEXX’s revenue is closely tied to how often pet owners visit veterinary clinics, whether veterinarians recommend diagnostic testing, and whether pet owners approve those recommendations. When households face pressure from inflation, higher living costs, or broader economic uncertainty, they may become more selective about spending on non-urgent veterinary care. This is particularly visible in wellness visits and more discretionary procedures such as dental cleanings, routine blood panels, and preventive screenings. These types of visits are often the first to be delayed when budgets become tighter. This dynamic has already been visible in the industry. Same-store clinical visits in the U.S. have declined, with management indicating pressure particularly in wellness and discretionary visits rather than acute care. In other words, pet owners are still generally willing to pay when something is clearly wrong with the animal, but they may postpone routine checkups or optional diagnostic work when facing financial pressure. This matters for IDEXX because many of its diagnostic tests are tied to routine visits and preventive care protocols. Fewer wellness visits can therefore directly reduce test volumes across its installed base of analyzers and reference laboratories. Another macroeconomic risk is that slower pet adoption and replacement rates can affect long-term growth. When consumers feel financially constrained, they may delay adding a new pet to the household. This has knock-on effects for IDEXX because younger pets typically drive frequent early-life veterinary visits, vaccinations, wellness exams, and diagnostic testing. Management has already noted softer puppy and kitten visits, which suggests that economic pressure is influencing pet ownership decisions at the margin. Macroeconomic weakness can also affect veterinary clinics themselves. If clinics experience lower visit volumes or increased pushback on pricing, they may become more cautious about purchasing new capital equipment such as IDEXX analyzers, imaging systems, or software upgrades. Since IDEXX’s model depends partly on continued instrument placements that then drive recurring consumable sales, any slowdown in new placements can weigh on future growth. Even if existing recurring revenue remains resilient, weaker instrument adoption today can reduce the growth of the installed base tomorrow. The risk extends beyond companion animal diagnostics. IDEXX’s Water and Livestock segments are also exposed to economic conditions because demand depends partly on budgets at government laboratories, utilities, and agricultural producers. In weaker economic environments, these customers may delay testing investments or reduce spending, which can affect demand in those segments as well.

Relying on third-party suppliers is a risk for IDEXX Laboratories because a large part of its ability to manufacture products, deliver services, and maintain customer trust depends on external partners. IDEXX relies on outside suppliers for critical components, raw materials, biological materials, cloud infrastructure, and even some finished products. This means that any disruption at a supplier, whether caused by shortages, production delays, financial difficulties, transportation issues, or geopolitical events, can directly affect IDEXX’s ability to deliver products to customers on time. For a company whose business model depends heavily on recurring revenue from consumables and ongoing diagnostic testing, even temporary supply disruptions can have a meaningful impact on sales and customer relationships. One of the most important risks is IDEXX’s reliance on sole or single-source suppliers for certain components and proprietary materials. In simple terms, this means that for some parts there may only be one supplier, or a very limited number of suppliers, capable of providing what IDEXX needs. This is especially important for specialized components used in diagnostic instruments, cartridges, test kits, and water testing products. If one of these suppliers experiences operational problems or cannot meet demand, IDEXX may not be able to quickly replace them. Even when an alternative supplier exists, switching is often slow and costly because the new parts must be tested, approved, and integrated into the products. In some cases, regulatory approval may also be required before IDEXX can use a replacement supplier, which can further delay production. This risk is particularly relevant because IDEXX’s reputation is built on reliability and daily workflow integration within veterinary clinics. If clinics cannot receive analyzers, consumables, or replacement parts when needed, this can disrupt their operations and potentially push them to consider alternative providers. Since IDEXX’s moat partly depends on high customer retention and recurring consumable revenue, prolonged supply chain issues could damage both growth and long-term customer loyalty. The risk also extends beyond physical products. IDEXX increasingly relies on cloud-based software solutions and connected diagnostic platforms. This means the company also depends on third-party cloud infrastructure providers and digital service partners. Any disruption, outage, or cybersecurity issue at these providers could temporarily affect software availability, diagnostic workflows, and customer confidence.

Reasons to invest

Innovations is a reason to invest in IDEXX Laboratories because innovation is one of the most important drivers behind the company’s long-term growth, competitive moat, and ability to expand its addressable market. IDEXX has consistently shown that it does not rely only on price increases or general industry growth to deliver results. Instead, it creates new revenue opportunities through new platforms, test menus, and software solutions that improve workflows for veterinary clinics and raise the standard of care. This strategy was clearly visible in 2025, which management itself described as a defining year driven by successful execution of its innovation-led growth strategy. One of the clearest examples is the launch and rapid adoption of the IDEXX inVue Dx platform. This has been one of the most successful product launches in the company’s history, with nearly 6.400 placements in 2025 and more than $75 million in instrument revenue. More importantly, this is not just one-time instrument revenue. Once the platform is placed, it begins to generate recurring consumable revenue and drives higher diagnostic utilization over time. The platform addresses an important pain point in veterinary clinics by automating cytology and reducing the need for manual slide preparation and microscope analysis. By combining automation with AI-powered analysis, clinics can receive results within minutes while the patient is still in the clinic. This improves productivity, supports better clinical decisions, and makes it easier for clinics to perform tests that may previously have been skipped because they were too time-consuming. In other words, IDEXX is not only selling a new machine but also helping clinics perform more tests per visit, which supports recurring growth. Another major reason innovation supports the investment case is the expansion into oncology diagnostics through Cancer Dx. This is particularly exciting because it opens a large new category within veterinary diagnostics. Early cancer detection in pets is still a relatively underpenetrated area, and IDEXX is helping create this market rather than simply competing within an established one. The Cancer Dx panel allows veterinarians to screen for diseases such as canine lymphoma using a simple blood test during routine wellness visits. Management highlighted that lymphoma signals can in some cases be detected up to eight months before clinical symptoms appear, which can meaningfully improve treatment outcomes. The ability to expand this panel to include mast cell tumor detection in 2026 further strengthens the opportunity. Over time, management believes this category alone could represent an opportunity of approximately $1,1 billion, which highlights how innovation can materially expand IDEXX’s long-term growth runway. Innovation also strengthens IDEXX’s moat by increasing the value of its existing installed base. One of the most attractive parts of the business model is that new tests and software capabilities can often be rolled out across already installed platforms. The Catalyst system is a great example. IDEXX now has approximately 78.000 Catalyst instruments globally, and new test additions such as Pancreatic Lipase and Cortisol can be introduced across this installed base with relatively limited additional capital requirements. This means that the economic value of each instrument increases over time. Management even noted that the economic value of Catalyst instruments has increased approximately 2,5 times over the past decade as a result of continuous innovation. This is a very powerful model because it drives higher utilization and consumable revenue without needing to place entirely new systems.

Software is a reason to invest in IDEXX Laboratories because it strengthens the company’s moat, supports highly recurring revenue, and makes the broader diagnostic ecosystem even more difficult for customers to leave. While diagnostics remain the largest revenue driver, software is what increasingly turns IDEXX from a product provider into the operating system of the veterinary clinic. The company’s software platforms help clinics manage scheduling, patient records, billing, diagnostics, imaging, and communication with pet owners, all within one connected ecosystem. This not only improves clinic efficiency but also increases the value of IDEXX’s instruments and laboratory services. One of the most attractive aspects of the software business is its recurring nature. Cloud-based practice management systems such as ezyVet and Neo generate recurring subscription revenue that tends to be highly predictable and high margin. Management has highlighted continued double-digit growth in recurring software revenue, particularly within its cloud-based platforms. This is important because software revenue typically carries strong margins and requires relatively limited incremental costs as the customer base grows. In other words, as more clinics adopt the platform, a large share of each additional dollar of revenue can turn into profit and free cash flow. Another key reason software strengthens the investment case is that it increases customer stickiness. Once a veterinary clinic uses IDEXX software to manage appointments, patient records, billing, imaging, and diagnostics, switching becomes highly disruptive. Moving to another provider would require data migration, staff retraining, and workflow changes, all of which create friction. This significantly raises switching costs and helps protect IDEXX’s diagnostic business as well. In many ways, software builds the wall around the customer. Even if a competitor offers lower-cost diagnostic tools, it becomes much harder for a clinic to switch if its entire workflow is already built around IDEXX’s systems. The integration between software and diagnostics is particularly powerful. For example, when a veterinarian orders a test through the software, the diagnostic analyzer can automatically prepare, and once the test is completed the results flow directly into the patient record. This seamless workflow improves productivity and reduces manual work for staff. More importantly from an investment perspective, it encourages higher diagnostic usage. Management has specifically noted that clinics using IDEXX software solutions tend to use more diagnostics, which increases lifetime customer value. Vello is another strong example of why software is a reason to invest. This pet-owner engagement platform helps clinics improve communication with pet owners, reduce missed appointments, and improve compliance with diagnostics and treatment plans. Management noted that Vello users nearly tripled year over year. Clinics using Vello have reported more visits and better compliance, which directly supports higher diagnostic volumes. This is important because software is not only generating revenue on its own but also driving growth across the broader IDEXX ecosystem. The shift toward cloud-native platforms is another positive long-term trend. More clinics are moving toward modern cloud-based systems because they are easier to scale, particularly for multi-location practices and corporate groups. IDEXX’s strong momentum in ezyVet and Neo positions the company well to benefit from this transition. As the industry continues to consolidate and larger clinic groups seek centralized systems, this part of the business could become an increasingly important growth driver.

The deepening human-animal bond is a reason to invest in IDEXX Laboratories because it provides one of the strongest and most durable long-term demand drivers for the company’s business. More and more pet owners view their animals as family members rather than simply pets, and this shift continues to increase spending on veterinary care, diagnostics, and preventive treatment. This trend is particularly important for IDEXX because the company benefits directly from more veterinary visits, higher testing frequency, and greater willingness from owners to approve advanced diagnostic work. One of the clearest effects of the stronger human-animal bond is that pet owners are increasingly willing to spend on high-quality care, even during more challenging economic periods. Management has highlighted that this commitment remains visible despite pressure on household budgets. While some owners may postpone wellness visits, when they do come into the clinic they are increasingly willing to proceed with diagnostic testing. This is important because it means IDEXX is benefiting not only from visit volumes but also from higher diagnostic intensity per visit. Another major driver is the aging pet population. Pets adopted during the pandemic are now moving into their adult and senior years, which naturally leads to greater healthcare needs. Just as humans require more medical testing as they age, the same is true for pets. Older dogs and cats are more likely to develop chronic conditions such as kidney disease, diabetes, arthritis, endocrine disorders, and cancer. These conditions require screening, monitoring, and repeated testing over time, all of which support demand for IDEXX’s diagnostic instruments, consumables, and reference laboratory services. Management has already pointed to early signs of improving visit growth among pets aged 5 years and older, which is an encouraging signal that this trend is beginning to contribute meaningfully to growth. This trend is particularly attractive because it is likely to be long-lasting rather than temporary. The pandemic pet adoption wave created a large cohort of animals that will continue to age over the coming years. As these pets move from adult to senior stages, diagnostic needs are likely to increase further. In other words, the company is benefiting from a structural demand tailwind that could continue for many years. The deepening bond between owners and pets also supports preventive care and early detection, which is an area where IDEXX is especially well positioned. Pet owners who see their animals as family members are more likely to prioritize screenings and routine diagnostic panels even before symptoms become severe. This aligns perfectly with IDEXX’s strategy of expanding diagnostic frequency and introducing new tools such as Cancer Dx and advanced in-clinic analyzers. As owners increasingly want earlier detection and better long-term disease management, IDEXX’s products become even more valuable. Another important point is that pets are living longer thanks to better veterinary care. Longer life expectancy naturally increases the lifetime value of each pet from a diagnostics perspective. More years of life means more routine visits, more screenings, and more chronic disease management. This creates a powerful secular tailwind for IDEXX because it supports both higher test volumes and recurring revenue over time.

Unlock Exclusive Seeking Alpha Discounts – Level Up Your Investing With Zero Risk

If you’ve been thinking about improving your investing process, this is the easiest way to start. These offers are only available through my links, and the Premium plan even comes with a 100% risk-free 7-day trial. Try everything for a week, and if it’s not for you, just cancel. You lose nothing.

1) Seeking Alpha Premium — Try It Free for 7 Days

Access the tools I personally use every day:

• Earnings transcripts

• Stock screeners

• Deep-dive analysis

• Portfolio tracking

• Market news with context that actually matters

Special Price: $269/year (normally $299) + 7-day free trial (for new users only)

Try Premium Free for 7 Days → HERE

(Explore everything — cancel anytime during the trial and pay $0.)

2) Alpha Picks — Proven Stock Ideas

This stock-picking service has delivered +287% returns vs. the S&P 500’s +77% (July 2022–Nov 2025).Great for investors who want curated, long-term picks backed by data.

Special Price: $449/year (normally $499)

Get Alpha Picks → HERE

(Although Alpha Picks doesn’t offer a free trial, its historical outperformance means the subscription can often pay for itself quickly if results persist. For many investors, the potential return far outweighs the upfront cost).

3) Premium + Alpha Picks Bundle — Best Value

Get both services together and save $159.Perfect if you want both broad tools and high-conviction stock ideas.

Special Price: $639/year (normally $798)

Get the Bundle → HERE

(This bundle doesn’t include a free trial, but it gives you both services at a $159 discount. You get Premium’s in-depth research plus Alpha Picks’ high-performing recommendations, making it the most comprehensive option for serious investors.)

Valuation

Now it is time to calculate the share price. I perform three different calculations that I learned at a Phil Town seminar. If you want to make the calculations yourself for this or other stocks, you can do so through the tools page on my website, where you have access to all three calculators for free.

The first is called the Margin of Safety price, which is calculated based on earnings per share (EPS), estimated future EPS growth, and estimated future price-to-earnings ratio (P/E). The minimum acceptable rate of return is 15%. I chose to use an EPS of 13,08, which is from the year 2025. I have selected a projected future EPS growth rate of 12%. Finbox expects EPS to grow by 11,6% in the next five years. Additionally, I have selected a projected future P/E ratio of 30, which is double the growth rate. This decision is based on IDEXX's historically higher price-to-earnings (P/E) ratio. Finally, our minimum acceptable rate of return has already been established at 15%. After performing the calculations, we determined the sticker price (also known as fair value or intrinsic value) to be $241,00,. We want to have a margin of safety of 50%, so we will divide it by 2. This means that we want to buy IDEXX at a price of $120,50 (or lower, obviously) if we use the Margin of Safety price.

The second calculation is known as the Ten Cap price. The rate of return that a company owner (or stockholder) receives on the purchase price of the company essentially represents its return on investment. The minimum annual return should be at least 10%, which I calculate as follows: The operating cash flow last year was 1.182, and capital expenditures were 125. I attempted to analyze their annual report to calculate the percentage of capital expenditures allocated to maintenance. I couldn't find it, but as a rule of thumb, you can expect that 70% of the capital expenditures will be allocated to maintenance purposes. This means that we will use 88 in our calculations. The tax provision was 265. We have 79,9 outstanding shares. Hence, the calculation will be as follows: (1.182 – 88 + 265) / 79,9 x 10 = $170,09 in Ten Cap price.

The final calculation is referred to as the Payback Time price. It is a calculation based on the free cash flow per share. With IDEXX's free cash flow per share at $13.24 and a growth rate of 12%, if you want to recoup your investment in 8 years, the Payback Time price is $182,39.

Conclusion

IDEXX Laboratories is an intriguing company with strong management. The company has built its moat through its integrated ecosystem, high switching costs, recurring revenue model, and strong brand reputation within veterinary healthcare. IDEXX has consistently achieved a high ROIC, which is a trend that is expected to continue given its capital-light, high-margin business model and strong customer retention. IDEXX also delivered its highest free cash flow and free cash flow margin ever in 2025, and free cash flow is expected to continue growing over the long term as instrument placements, consumable sales, and software revenue expand. Competition is a risk for IDEXX Laboratories because it operates in an attractive and fast-growing market that continues to draw well-funded competitors such as Zoetis and Mars Incorporated, which can compete through lower pricing, product bundling, and continued innovation. If the technology gap narrows or large veterinary groups increasingly favor in-house solutions, IDEXX could face pressure on instrument placements, recurring consumable sales, and long-term margins. Macroeconomic factors are a risk for IDEXX Laboratories because inflation and broader economic pressure can lead pet owners to delay wellness visits, preventive screenings, and other non-urgent procedures, which directly reduces diagnostic test volumes. In addition, weaker clinic spending and slower pet adoption can weigh on new instrument placements and long-term recurring revenue growth. Relying on third-party suppliers is a risk for IDEXX Laboratories because disruptions in critical components, raw materials, or cloud infrastructure can delay product deliveries, disrupt clinic workflows, and weaken customer trust. This risk is amplified by the company’s reliance on sole or single-source suppliers for certain specialized parts, where replacing a supplier can be both time-consuming and costly. Innovations is a reason to invest in IDEXX Laboratories because continuous product launches such as inVue Dx and Cancer Dx expand the company’s addressable market, drive recurring consumable revenue, and strengthen its competitive moat. Just as importantly, new tests and software features can be rolled out across the large existing installed base, increasing instrument utilization and the long-term value of each placement. Software is a reason to invest in IDEXX Laboratories because it generates highly recurring, high-margin revenue while making the company’s diagnostic ecosystem significantly harder for customers to leave. By integrating scheduling, patient records, imaging, diagnostics, and pet-owner communication into one platform, software both raises switching costs and encourages higher diagnostic usage, which increases customer lifetime value. The deepening human-animal bond is a reason to invest in IDEXX Laboratories because pet owners increasingly view their animals as family members, which supports higher spending on veterinary care, preventive screenings, and advanced diagnostics. Combined with an aging pet population and longer pet lifespans, this creates a durable long-term tailwind for higher test volumes and recurring revenue growth. Overall, I believe that IDEXX Laboratories is a great company, and buying shares around $364, which is the intrinsic value based on the Payback Time price, could represent an attractive long-term investment.

My personal goal with investing is financial freedom. It also means that to obtain that, I do different things to build my wealth. If you have some extra hours to spare each month, you can turn a few hours a week into a substantial amount of money in a few years. If you are interested to know how to do it, you can read this post.

I hope you enjoyed my analysis! While I can’t post about every company I analyze, you can stay updated on my trades by following me on Twitter. I share real-time updates whenever I buy or sell, so if you’re making your own investment decisions, be sure to follow along!

Some of the greatest investors in the world believe in karma, and to receive, you will have to give (Warren Buffett and Mohnish Pabrai are great examples). If you appreciated my analysis and want to get some good karma, I would kindly ask you to donate a bit to Soi Dog. They rescue street dogs in Thailand by giving them food, medicine and vet care. If you have a little to spare, please donate here. Even a little will make a huge difference to save these wonderful animals. Thank you.